Doc Pharma is a pharmaceutical company founded in 2015 with the aim to introduce into the market innovative healthcare products and food supplements promoting health and wellbeing. The Company is engaged in developing, manufacturing, marketing, distributing and exporting generics and proprietary brands of food supplements. Furthermore, the Company operates as a wholesaler or pharmaceutical products and cosmetics, distributing and exporting to the European market, and expanding its network worldwide.

The Company is headquartered in Thessaloniki, Greece and the manufacturing facility is in Pallini, Athens. The facilities are certified from the National Organisation for Medicines (E.O.F) for observing the guidelines on good manufacturing practice (GMP) and good distribution practice (GDP). Additionally, the Company is ISO 9001 certified.

On May 20, 2016, Cosmos Holdings Inc. entered into a non-binding Memorandum of Understanding with DOC Pharma SA, a company controlled by Grigorios Siokas, the Company's CEO, a director and principal shareholder. DOC Pharma SA located in Thessaloniki, Greece, is an ISO certified and licensed GDP (Good Distribution Practices) wholesaler of pharmaceutical products. It is the owner of numerous licenses of generic medicines and uses its own network of pharmaceutical sales representatives to communicate its products with doctors. The Company also trades name brand medicines, food supplements, and cosmetics.

The purchase price to be determined is expected to be a combination of cash and shares of Cosmos stock. Closing of the transaction on or before December 31, 2016, is subject to execution of definitive exchange agreements, a full audit of DOC Pharma, satisfactory completion of due diligence of DOC Pharma, tax and legal considerations, and other customary closing conditions.